Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Optoceutics Aps currently manages 1 pending office action. This matter is assigned to 1 distinct examiner, CIRULNICK, EMILY NICOLE, who is responsible for the 1 pending action. The data shows 0 distinct art units associated with this portfolio, concentrating the current prosecution activity under a single examiner's review. This focus suggests that the company's immediate patent outcomes are tied to the specific requirements and feedback of this individual examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CIRULNICK, EMILY NICOLE | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572326 | PHOTOTHERAPEUTIC APPARATUS | CIRULNICK, EMILY NICOLE | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572326 | PHOTOTHERAPEUTIC APPARATUS | CIRULNICK, EMILY NICOLE | — | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial